These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Quantitative structure-activity relationship analysis of thiazolidineones: potent antidiabetic compounds. Vishvakarma VK; Singh P; Dubey M; Kumari K; Chandra R; Pandey ND Drug Metabol Drug Interact; 2013; 28(1):31-47. PubMed ID: 23417104 [TBL] [Abstract][Full Text] [Related]
23. Discovery of the bifunctional modulator of angiotensin II type 1 receptor (AT1R) and PPARγ derived from the AT1R antagonist, Fimasartan. Choung W; Jung HJ; Nam EH; Yang D; Yoo B; Choi H; Lee BR; Park M; Jang SM; Lim JS; Kim KH; Chin J; Jung K; Lee G; Kim SH Bioorg Med Chem Lett; 2018 Oct; 28(19):3155-3160. PubMed ID: 30177375 [TBL] [Abstract][Full Text] [Related]
24. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ. Han L; Shen WJ; Bittner S; Kraemer FB; Azhar S Future Cardiol; 2017 May; 13(3):279-296. PubMed ID: 28581362 [TBL] [Abstract][Full Text] [Related]
25. Effects of Avocado (Persea americana) on Metabolic Syndrome: A Comprehensive Systematic Review. Tabeshpour J; Razavi BM; Hosseinzadeh H Phytother Res; 2017 Jun; 31(6):819-837. PubMed ID: 28393409 [TBL] [Abstract][Full Text] [Related]
26. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists. Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518 [TBL] [Abstract][Full Text] [Related]
27. PPAR Agonists and Metabolic Syndrome: An Established Role? Botta M; Audano M; Sahebkar A; Sirtori CR; Mitro N; Ruscica M Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662003 [TBL] [Abstract][Full Text] [Related]
31. Molecular determinants of PPARγ partial agonism and related in silico/in vivo studies of natural saponins as potential type 2 diabetes modulators. Al Sharif M; Alov P; Diukendjieva A; Vitcheva V; Simeonova R; Krasteva I; Shkondrov A; Tsakovska I; Pajeva I Food Chem Toxicol; 2018 Feb; 112():47-59. PubMed ID: 29247773 [TBL] [Abstract][Full Text] [Related]
32. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Kurtz TW Acta Diabetol; 2005 Apr; 42 Suppl 1():S9-16. PubMed ID: 15868121 [TBL] [Abstract][Full Text] [Related]
33. Identification of novel PPARα/γ dual agonists by pharmacophore screening, docking analysis, ADMET prediction and molecular dynamics simulations. Feng XY; Jia WQ; Liu X; Jing Z; Liu YY; Xu WR; Cheng XC Comput Biol Chem; 2019 Feb; 78():178-189. PubMed ID: 30557816 [TBL] [Abstract][Full Text] [Related]
34. N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators. Blöcher R; Lamers C; Wittmann SK; Merk D; Hartmann M; Weizel L; Diehl O; Brüggerhoff A; Boß M; Kaiser A; Schader T; Göbel T; Grundmann M; Angioni C; Heering J; Geisslinger G; Wurglics M; Kostenis E; Brüne B; Steinhilber D; Schubert-Zsilavecz M; Kahnt AS; Proschak E J Med Chem; 2016 Jan; 59(1):61-81. PubMed ID: 26595749 [TBL] [Abstract][Full Text] [Related]
35. Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents. Henry JR; Li Y; Warshawsky AM; Brozinick JT; Hawkins ED; Misener EA; Briere DA; Montrose-Rafizadeh C; Zink RW; Yumibe NP; Ajamie RT; Wilken B; Devanarayan V Bioorg Med Chem Lett; 2006 Dec; 16(24):6293-7. PubMed ID: 17005393 [TBL] [Abstract][Full Text] [Related]
36. Effects of a PPAR-gamma receptor agonist and an angiotensin receptor antagonist on aortic contractile responses to alpha receptor agonists in diabetic and/or hypertensive rats. Tugrul I; Dost T; Demir O; Gokalp F; Oz O; Girit N; Birincioglu M Cardiovasc J Afr; 2016 May/Jun 23; 27(3):164-169. PubMed ID: 27149161 [TBL] [Abstract][Full Text] [Related]
37. PPAR-gamma agonists and their role in type 2 diabetes mellitus management. Bermúdez V; Finol F; Parra N; Parra M; Pérez A; Peñaranda L; Vílchez D; Rojas J; Arráiz N; Velasco M Am J Ther; 2010; 17(3):274-83. PubMed ID: 20216208 [TBL] [Abstract][Full Text] [Related]
38. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Fiévet C; Fruchart JC; Staels B Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418 [TBL] [Abstract][Full Text] [Related]
39. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators. Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604 [TBL] [Abstract][Full Text] [Related]
40. Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ. Casimiro-Garcia A; Filzen GF; Flynn D; Bigge CF; Chen J; Davis JA; Dudley DA; Edmunds JJ; Esmaeil N; Geyer A; Heemstra RJ; Jalaie M; Ohren JF; Ostroski R; Ellis T; Schaum RP; Stoner C J Med Chem; 2011 Jun; 54(12):4219-33. PubMed ID: 21557540 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]